MARKET

AVXL

AVXL

Anavex Life
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.200
-0.040
-0.94%
After Hours: 4.190 -0.01 -0.24% 18:04 08/07 EDT
OPEN
4.190
PREV CLOSE
4.240
HIGH
4.310
LOW
3.865
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
6.31
52 WEEK LOW
2.200
MARKET CAP
252.35M
P/E (TTM)
-9.1166
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AVXL stock price target is 11.50 with a high estimate of 16.00 and a low estimate of 8.00.

EPS

AVXL News

More
Anavex Life Sciences EPS beats by $0.03
Anavex Life Sciences (NASDAQ:AVXL): Q3 GAAP EPS of -$0.11 beats by $0.03. Cash and cash equivalents of $27.6M. Press Release
seekingalpha · 1d ago
Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates
Conference Call and Webcast Today at 11:00 a.m. ETNEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treat
GlobeNewswire · 2d ago
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients
Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical StudyNEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences
GlobeNewswire · 2d ago
Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020
Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern TimeNEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differ
GlobeNewswire · 4d ago
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
Anavex Is Likely To Report Positive Parkinson's Disease Trial Results For A2-73, Increasing Share Value
Seeking Alpha - Article · 07/07 18:33
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
GlobeNewswire · 07/06 12:00
dosing underway in Anavex Life's early-stage ANAVEX3-71 study
Seeking Alpha - Article · 07/06 11:53

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About AVXL

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.
More

Webull offers kinds of Anavex Life Sciences Corp stock information, including NASDAQ:AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.